Intercept names senior VP, medical affairs
This article was originally published in Scrip
Intercept Pharmaceuticals, a clinical stage biopharmaceutical company developing novel therapeutics to treat chronic underserved liver diseases such as primary biliary cirrhosis (PBC) and nonalcoholic steatohepatitis (NASH), has appointed Dr Juan Carlos Lopez-Talavera senior vice-president of medical affairs. Dr Lopez-Talavera was most recently head of hepatology R&D and vice-president of medical affairs at AbbVie, where he was responsible for all medical affairs activities supporting the global launch of AbbVie's regimen for the treatment of hepatitis C.
You may also be interested in...
UK special envoy on antimicrobial resistance Professor Dame Sally Davies, who is also the former chief medical officer for England, talks to In Vivo about the challenges of 2020, the importance of a strong working relationship between the public and private sectors, and reaching a turning point on AMR.
It is time for In Vivo's 13th annual Deals of the Year contest. We've selected 15 nominees in three categories – Top Alliance, Top Financing and Top M&A – and you get to pick the winners.
Derived from Biomedtracker, the Deal-Making column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in October 2020. Data provided by Biomedtracker.